104 related articles for article (PubMed ID: 38954891)
1. Impact of vortioxetine on depressive symptoms moderated by symptoms of anxiety in persons with post-COVID-19 condition: A secondary analysis.
Le GH; Kwan ATH; Guo Z; Teopiz KM; Wong S; Meshkat S; d'Andrea G; Ho R; Rhee TG; Cao B; Badulescu S; Phan L; Rosenblat JD; Mansur RB; Subramaniapillai M; McIntyre RS
Psychiatry Res; 2024 Jun; 339():116068. PubMed ID: 38954891
[TBL] [Abstract][Full Text] [Related]
2. Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine.
Kwan ATH; Guo Z; Ceban F; Le GH; Wong S; Teopiz KM; Rhee TG; Ho R; Di Vincenzo JD; Badulescu S; Meshkat S; Cao B; Rosenblat JD; d'Andrea G; Dev DA; Phan L; Subramaniapillai M; McIntyre RS
Adv Ther; 2024 May; 41(5):1983-1994. PubMed ID: 38520501
[TBL] [Abstract][Full Text] [Related]
3. Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial.
McIntyre RS; Phan L; Kwan ATH; Mansur RB; Rosenblat JD; Guo Z; Le GH; Lui LMW; Teopiz KM; Ceban F; Lee Y; Bailey J; Ramachandra R; Di Vincenzo J; Badulescu S; Gill H; Drzadzewski P; Subramaniapillai M
Brain; 2024 Mar; 147(3):849-857. PubMed ID: 37936330
[TBL] [Abstract][Full Text] [Related]
4. Association between fatigue and depressive symptoms in persons with post-COVID-19 condition: a post hoc analysis.
Teopiz KM; Kwan ATH; Le GH; Guo Z; Badulescu S; Ceban F; Meshkat S; Di Vincenzo JD; d'Andrea G; Cao B; Ho R; Rhee TG; Dev DA; Phan L; Subramaniapillai M; Mansur RB; Rosenblat JD; McIntyre RS
Curr Med Res Opin; 2024 Jul; 40(7):1203-1209. PubMed ID: 38860901
[TBL] [Abstract][Full Text] [Related]
5. Impact of Baseline Anxiety on Well-being in People with Post-COVID-19 Condition: A Secondary Analysis.
Kleine N; Kwan ATH; Le GH; Guo Z; Phan L; Subramaniapillai M; McIntyre RS
CNS Spectr; 2024 Apr; 29(2):150-154. PubMed ID: 38453677
[TBL] [Abstract][Full Text] [Related]
6. Impact of vortioxetine on psychosocial functioning moderated by symptoms of fatigue in post-COVID-19 condition: a secondary analysis.
Badulescu S; Le GH; Wong S; Kwan ATH; Guo Z; Teopiz KM; Phan L; Subramaniapillai M; Rosenblat JD; Mansur RB; McIntyre RS
Neurol Sci; 2024 Apr; 45(4):1335-1342. PubMed ID: 38321333
[TBL] [Abstract][Full Text] [Related]
7. Impact of Elevated Body Mass Index (BMI) on Hedonic Tone in Persons with Post-COVID-19 Condition: A Secondary Analysis.
Le GH; Kwan ATH; Wong S; Guo Z; Teopiz KM; Badulescu S; Meshkat S; d'Andrea G; Ho R; Rhee TG; Cao B; Phan L; Rosenblat JD; Mansur RB; Subramaniapillai M; McIntyre RS
Adv Ther; 2024 Feb; 41(2):686-695. PubMed ID: 38114867
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study.
Almeida SS; Christensen MC; Simonsen K; Adair M
J Psychopharmacol; 2023 Mar; 37(3):279-288. PubMed ID: 36377523
[TBL] [Abstract][Full Text] [Related]
9. Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the AtWoRC study.
Chokka P; Ge H; Bougie J; Ettrup A; Clerzius G
Ther Adv Psychopharmacol; 2021; 11():20451253211013148. PubMed ID: 34025982
[TBL] [Abstract][Full Text] [Related]
10. Vortioxetine for depression in adults.
Koesters M; Ostuzzi G; Guaiana G; Breilmann J; Barbui C
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011520. PubMed ID: 28677828
[TBL] [Abstract][Full Text] [Related]
11. Impacts of metabolic disruption, body mass index and inflammation on cognitive function in post-COVID-19 condition: a randomized controlled trial on vortioxetine.
Kwan ATH; Le GH; Guo Z; Ceban F; Teopiz KM; Rhee TG; Ho R; Di Vincenzo JD; Badulescu S; Meshkat S; Cao B; Rosenblat JD; Dev DA; Phan L; Subramaniapillai M; McIntyre RS
Ann Gen Psychiatry; 2024 Feb; 23(1):10. PubMed ID: 38424537
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of vortioxetine in working patients with generalized anxiety disorder.
Christensen MC; Loft H; Florea I; McIntyre RS
CNS Spectr; 2019 Apr; 24(2):249-257. PubMed ID: 29081307
[TBL] [Abstract][Full Text] [Related]
13. Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability.
Adair M; Christensen MC; Florea I; Loft H; Fagiolini A
J Affect Disord; 2023 May; 328():345-354. PubMed ID: 36708956
[TBL] [Abstract][Full Text] [Related]
14. Relationship between anhedonia and psychosocial functioning in post-COVID-19 condition: a
Liao S; Teopiz KM; Kwan ATH; Le GH; Wong S; Ballum H; Rhee TG; Badulescu S; Cao B; Guo Z; Meshkat S; Phan L; Subramaniapillai M; Ho R; McIntyre RS
Curr Med Res Opin; 2024 Jul; ():1-5. PubMed ID: 38954402
[TBL] [Abstract][Full Text] [Related]
15. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis.
Jacobsen PL; Mahableshwarkar AR; Palo WA; Chen Y; Dragheim M; Clayton AH
CNS Spectr; 2016 Oct; 21(5):367-378. PubMed ID: 26575433
[TBL] [Abstract][Full Text] [Related]
16. Central monitoring of depression and anxiety symptoms reduces placebo responses in depression clinical trials: A post hoc exploratory analysis of data from the phase III CCT-004 trial of vortioxetine.
Watanabe Y; Nishimura A; Kikuchi T; Sawada N; Imazaki M; Inada I; Watanabe K
Neuropsychopharmacol Rep; 2022 Dec; 42(4):468-477. PubMed ID: 36151855
[TBL] [Abstract][Full Text] [Related]
17. Impact of elevated body mass index (BMI) on cognitive functioning and inflammation in persons with post-COVID-19 condition: a secondary analysis.
Le GH; Kwan ATH; Guo Z; Wong S; Badulescu S; Gill H; Teopiz KM; Meshkat S; Ceban F; Phan L; Subramaniapillai M; Di Vincenzo JD; Rosenblat JD; Mansur RB; d'Andrea G; Ho R; Rhee TG; McIntyre RS
Acta Neuropsychiatr; 2024 Apr; ():1-7. PubMed ID: 38605630
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study.
Christensen MC; Schmidt S; Grande I
J Psychopharmacol; 2022 May; 36(5):566-577. PubMed ID: 35499104
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Potential of Vortioxetine for Anxious Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan.
Inoue T; Fujimoto S; Marumoto T; Kitagawa T; Ishida K; Nakajima T; Moriguchi Y; Fujikawa K; Watanabe K
Neuropsychiatr Dis Treat; 2021; 17():3781-3790. PubMed ID: 34992372
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
